Headache methylphenidate

The side effects of methylphenidate are very similar to the amphetamines, but because it is somewhat less potent they may be a little milder. The common side effects of methylphenidate are appetite loss, weight loss, insomnia, and nausea. Taking methylphenidate with meals and no later than 6 PM can control most of these. On rare occasions, methylphenidate can cause headache, dizziness, nervousness, increased heart rate, increased blood pressure, tics, and, in extremely rare cases, paranoia. 

The adverse effects associated with methylphenidate are generally mild and short-lived, with the most common effects being insomnia, decreased appetite, stomach ache, headache, and jitteriness. Although methylphenidate has been abused, the problem of abuse is generally seen in adults who use multiple substances or in adolescents experimenting with medications (28). Sweden withdrew methylphenidate from its market in 1968 because some adults dissolved tablets and injected the solution, leading to serious cases of talc granulomatosis (38). However, most cases of methylphenidate abuse apparently have led to less serious consequences (28). 

As with methylphenidate, the adverse effects associated with pemoline are generally mild. The most common effects are insomnia, decreased appetite, stomachache, headache, and jitteriness (28). Periodic monitoring of liver enzymes is necessary because of the potential for hepatic toxic effects. 

Methylphenidate (Ritalin Ritalin SR Concerta Metadate) doses range from 5 mg/day bid to a maximum of 60 mg/day, divided fid. Side effects include nervousness, insomnia, loss of appetite and headaches. 

Q7 Side effects of methylphenidate are appetite suppression, nausea, abdominal pain, nervousness, irritability and insomnia. The patient s blood pressure needs to be checked as use of the drug may involve headaches and dizziness. In the long term, the medication may affect a child s height and weight and his growth should be monitored during prolonged treatment. The effectiveness of the medication should also be reassessed before the onset of puberty. 

Side effects of modafinil include headache, nausea, nervousness, and insomnia. Amphetamines and methylphenidate have a fast onset of effect and durations of 3 to 4 hours and 6 to 10 hours, respectively, for excessive... 

SYMPATHOMIMETICS CYTOTOXICS -PROCARBAZINE Co-administration of ephedrine, metaraminol, methylphenidate, phenylephrine or pseudoephedrine (including nasal and ophthalmic solutions) with procarbazine may cause a prolongation and t intensity of the cardiac stimulant effects and effects on BP, which may lead to headache, arrhythmias, hypertensive or hyperpyretic crisis The metabolism of sympathomimetics is impaired due to an inhibition of MAO It is recommended that sympathomimetics not be administered during and within 14 days of stopping procarbazine. Do not use any OTC nasal decongestants (sprays or oral preparations) or asthma relief agents without consulting the pharmacist/doctor... 

Hypertensive crisis with headache, intracranial bleeding, and death may result from combining MAO inhibitors with sympathomimetic drugs (e.g., amphetamines, methylphenidate, cocaine, dopamine, epinephrine, norepinephrine, and related compounds methyidopa,... 

A modified-release, once-daily formulation has been evaluated in 282 children with ADHD in a double-blind, placebo-controUed trial for 28 days (37). For core ADHD symptoms, both once-daily modified-release and thrice-daily immediate-release methylphenidate were superior to placebo and not different from each other. A similar percentage of patients reported at least one adverse event with both formulations. The most commonly reported adverse events were headache and upper respiratory infections, followed by abdominal pain, cough, pharyngitis, vomiting, and otitis media. Of these, only headache and abdominal pain were considered to be related to the study medication. One patient withdrew because of depression with modified-release methylphenidate and one because of tics with placebo. Headache occurred in 14%, 5.8%, and 10% of patients taking modified-release methylphenidate, immediate-release methylphenidate, or placebo respectively, and abdominal pain in 6.7%, 5.8%, and 1.0%. Other adverse events included appetite suppression (modified-release methylphenidate) and insomnia (aU three). The results of this study suggest that once-daily modified-release methylphenidate provides efficacy superior to placebo and is not significantly different from thrice-daily immediate-release methylphenidate. 

Ritalin methylphenidate psychostimulant ADHD, conduct disorder, autism appetite reduction, delay in falling asleep, headaches, weepiness, increased heart rate... 

Methylphenidate should not be used with monoamine oxidase inhibitors such as tranylcypromine. Symptoms of overdose may include euphoria, confusion, delirium, coma, toxic psychosis, agitation, headache, vomiting, dry mouth, mydriasis, self-injury, fever, diaphoresis, tremors, hyper-reflexia, muscle twitching, seizures, flushing, hypertension, tachycardia, palpitations, and arrhythmias. 

Sometimes doctors prescribe methylphenidate (Ritalin) or dextroamphetamine (Dexedrine) to treat a mood disorder called dysthymia that is less severe, but more chronic, than major depression. They work more quickly than antidepressants to pep you up, increasing energy and facilitating attention and concentration. Common side effects include nervousness, insomnia, constipation, headache, and changes in heart rate. 

Comparative trials Non-stimulant medications are being evaluated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents as alternatives to stimulants. In these studies reduced appetite and restlessness were more common with methylphenidate than with amantadine [54 ], and headache and insomnia were more common with methylphenidate than with venlafaxine [55 ]. Nevertheless, these studies do not constitute proof of efficacy. 

In a 6-week-randomised, double-blind study, 44 patients diagnosed with ADHD were randomly assigned to receive bupropion 100-150 mg/day or methylphenidate (20-30 mg/day) treatment. No serious events were observed in the study in any of the patients. The most commonly reported adverse events were abdominal pain (30%), anxiety (25%), decreased appetite (55%), agitation (20%), insomnia (50%), dizziness (5%), dry mouth (15%), nervousness (25%), tachycardia (5%), headache (50%) and vomiting (15%) [18 ]. In a randomised, double-blind. 

---